Zacks Research Upgrades Parabilis Medicines (NASDAQ:PBLS) to Hold

Parabilis Medicines (NASDAQ:PBLS) was upgraded by equities researchers at Zacks Research to a “hold” rating in a report released on Tuesday,Zacks.com reports.

A number of other equities research analysts have also recently weighed in on PBLS. Bank of America began coverage on shares of Parabilis Medicines in a research note on Monday. They set a “buy” rating and a $45.00 price objective on the stock. Evercore initiated coverage on shares of Parabilis Medicines in a research note on Monday. They set an “outperform” rating on the stock. Leerink Partners initiated coverage on shares of Parabilis Medicines in a research note on Monday. They issued an “outperform” rating and a $40.00 price target for the company. Wall Street Zen upgraded shares of Parabilis Medicines to a “hold” rating in a report on Saturday, June 20th. Finally, Guggenheim started coverage on shares of Parabilis Medicines in a research note on Monday. They set a “buy” rating and a $40.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, Parabilis Medicines currently has an average rating of “Buy” and an average target price of $41.67.

Parabilis Medicines Price Performance

Shares of PBLS stock opened at $30.83 on Tuesday. Parabilis Medicines has a 12-month low of $24.51 and a 12-month high of $34.47.

Insider Buying and Selling at Parabilis Medicines

In related news, Director Alan Sebulsky bought 9,065 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were bought at an average cost of $26.49 per share, with a total value of $240,131.85. Following the completion of the transaction, the director directly owned 30,000 shares of the company’s stock, valued at approximately $794,700. This trade represents a 43.30% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Guy Levy bought 500,000 shares of Parabilis Medicines stock in a transaction dated Thursday, June 11th. The shares were bought at an average cost of $20.00 per share, with a total value of $10,000,000.00. Following the completion of the acquisition, the insider owned 1,027,000 shares of the company’s stock, valued at $20,540,000. The trade was a 94.88% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have bought 530,000 shares of company stock valued at $10,723,528.

Key Headlines Impacting Parabilis Medicines

Here are the key news stories impacting Parabilis Medicines this week:

• Positive Sentiment: Lifesci Capital upgraded Parabilis Medicines to Strong-Buy and reiterated favorable earnings expectations across 2026 and 2027, signaling confidence in the company’s outlook. Tickerreport.com
• Positive Sentiment: Guggenheim initiated coverage on Parabilis Medicines with a Buy rating and a $40 price target, implying meaningful upside from current trading levels. Tickerreport.com
• Positive Sentiment: Bank of America and Leerink Partners also began coverage, adding to the growing analyst attention around PBLS and reinforcing investor interest. American Banking News
• Neutral Sentiment: Lifesci Capital’s detailed EPS estimates point to continued losses in several upcoming quarters and full years, which may temper enthusiasm despite the bullish rating. MarketBeat